Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single-agent post-transplant cyclophosphamide for GVHD prophylaxis after pediatric allogeneic stem cell transplantation
jRCTs031180399Phase 2Completed
- Sponsor
- National Center for Child Health and Development
- Start
- Nov 2016
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of cyclophosphamide in leukemia and lymphoma, sponsored by National Center for Child Health and Development. Primary endpoint: Cumulative incidence of acute graft-versus-host disease by day 100. Started Nov 2016; status: completed.
02
Drugs
cyclophosphamide
03
Conditions
leukemialymphoma
Beyond the preview
Go deeper on jRCTs031180399.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031180399.